Featured Publications
Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood
Cabrera‐Mendoza B, Stertz L, Najera K, Selvaraj S, Teixeira A, Meyer T, Fries G, Walss‐Bass C. Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2022, 192: 13-27. PMID: 36056652, PMCID: PMC9742183, DOI: 10.1002/ajmg.b.32920.Peer-Reviewed Original ResearchConceptsSubstance use disordersStimulant use disorderUse disordersPostmortem brainsAlcohol use disorderBrains of individualsBlood tissueBiological agingSubgroup analysisBrain valuesEpigenetic clocksSUD groupPeripheral measuresAging StudyDisordersBrainPatientsBloodDNA methylation changesSame individualTissueIndividualsMethylation changesOpioidsTissue specificityEstimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach
Cabrera-Mendoza B, Aydin N, Fries G, Docherty A, Walss-Bass C, Polimanti R. Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach. Neuropsychopharmacology 2024, 49: 1383-1391. PMID: 38396255, PMCID: PMC11250798, DOI: 10.1038/s41386-024-01833-2.Peer-Reviewed Original ResearchAssociated with higher oddsPsychiatric Genomics ConsortiumSubstance use disordersSocioeconomic factorsMendelian randomizationBipolar disorderGenetic liabilitySuicide attemptsHigher oddsTwo-sample Mendelian randomizationGenetic liability to bipolar disorderEffects of mental distressUK Biobank (UKBLiability to bipolar disorderMultivariable MR approachMendelian randomization approachComprehensive mental health assessmentGenome-wide association dataRisk of psychiatric disordersMental health assessmentBehavioral traitsAssociated with lonelinessHigh-risk individualsMental distressContext of SACandidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning
Cabrera‐Mendoza B, Martínez‐Magaña J, Monroy‐Jaramillo N, Genis‐Mendoza A, Fresno C, Fries GR, Walss‐Bass C, Armenta M, García‐Dolores F, Díaz‐Otañez C, Flores G, Vázquez‐Roque R, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2021, 186: 193-206. PMID: 33403748, DOI: 10.1002/ajmg.b.32830.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersBrain gene co-expression networksHub genesPotential pharmacological targetPost-mortem samplesPharmacological treatmentHigh riskCandidate treatmentPharmacological targetsSuicidal behaviorMAOA inhibitorsPrefrontal cortexNonsuicidesDGIdb databaseGene expression profilesPatientsCo-expression networkSuicideDisordersDrugsTreatmentDrug repositioningExpression profilesIndividualsBrain Gene Expression Profiling of Individuals With Dual Diagnosis Who Died by Suicide
Cabrera-Mendoza B, Fresno C, Monroy-Jaramillo N, Fries GR, Walss-Bass C, Glahn DC, Ostrosky-Wegman P, Genis-Mendoza AD, Martínez-Magaña JJ, Romero-Pimentel AL, Díaz-Otañez CE, García-Dolores F, González-Sáenz EE, Mendoza-Morales RC, Flores G, Vázquez-Roque R, Nicolini H. Brain Gene Expression Profiling of Individuals With Dual Diagnosis Who Died by Suicide. Journal Of Dual Diagnosis 2019, 16: 177-190. PMID: 31774731, DOI: 10.1080/15504263.2019.1692160.Peer-Reviewed Original ResearchConceptsSubstance use disordersMood disordersDual diagnosisUse disordersMental comorbiditiesGene expression profilesMental disordersSingle disorderCell type enrichmentAdverse clinical outcomesGlial-specific markersMore mental disordersExpression profilesDorsolateral prefrontal cortexClinical outcomesGABAergic neurotransmissionGlial markersHigh riskDisorder patientsComorbiditiesSuicidal behaviorPrefrontal cortexGene expression profilingSynaptic genesDisorders
2024
Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
Koller D, Mitjans M, Kouakou M, Friligkou E, Cabrera-Mendoza B, Deak J, Llonga N, Pathak G, Stiltner B, Løkhammer S, Levey D, Zhou H, Hatoum A, Kember R, Kranzler H, Stein M, Corominas R, Demontis D, Artigas M, Ramos-Quiroga J, Gelernter J, Ribasés M, Cormand B, Polimanti R. Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders. Psychiatry Research 2024, 333: 115758. PMID: 38335780, PMCID: PMC11157987, DOI: 10.1016/j.psychres.2024.115758.Peer-Reviewed Original ResearchConceptsUse disorderGenome-wide association studiesGenomic structural equation modelingCannabis use disorderAlcohol Use Disorders Identification TestAttention-deficit/hyperactivity disorderAlcohol use disorderProblematic alcohol useSubstance use disordersTwo-sample Mendelian randomization analysisLinkage disequilibrium score regression analysisDisorders Identification TestMendelian randomization analysisAssociated with increased oddsOdds of ADHDOpioid use disorderAttention-deficit/hyperactivityGWAS meta-analysesAlcohol dependenceStructural equation modelingNicotine dependenceInvestigate genetic correlationsADHDPolygenic riskStrength of evidence